Statera Biopharma, Inc. entered a Binding Memorandum of Understanding to acquire 25% in Holobeam Technologies, Inc. for $25 million on October 12, 2022. The consideration will be paid via the issuance of the Company's preferred stock or a combination of preferred stock and cash. The Transaction is subject to availability of at least $10 million on the balance sheet of the Statera Biopharma at the close of the Transaction, approval by a majority of HOLO's stockholders and approval by board of directors of Statera Biopharma, receipt of a fairness opinion by HOLO from an investment bank of its choosing and other customary conditions.